依维莫司联合依西美坦治疗激素受体阳性晚期转移性乳腺癌患者的作用评价  

Evaluation of the effect of everolimus combined with exemestane in the treatment ofhormone receptor-positive advanced metastatic breast cancer

作　　者：张晶 Zhang Jing(Department of Oncology and Hematology,First People's Hospital of Pingyuan County,Dezhou Shandong,253100,China)

机构地区：[1]平原县第一人民医院肿瘤血液内科,山东德州253100

出　　处：《中外女性健康研究》2021年第17期14-15,151,共3页Women＇s Health Research

摘　　要：目的:分析依维莫司联合依西美坦对激素受体阳性晚期转移性乳腺癌的治疗效果。方法:选取激素受体阳性晚期转移性乳腺癌患者72例进行研究,均2015年8月至2017年8月就诊于本院,经抽签法分组,对照组和观察组各为36例。对照组仅用依西美坦,观察组依维莫司与依西美坦联合使用,比较两组临床疗效、生存情况、治疗前后炎症因子水平。结果:观察组总缓解率为58.33%,高于对照组的33.33%,中位疾病进展时间为(4.78±1.24)个月,中位总生存期为(30.12±5.12)个月,长于对照组的(3.92±1.18)个月和(27.32±4.56)个月,组间对比有统计学差异(P<0.05);两组患者治疗前炎症因子水平对比无差异(P>0.05),观察组治疗后肿瘤坏死因子-α、白细胞介素-2、白细胞介素-6和白细胞介素-8水平低于对照组,组间对比有统计学差异(P<0.05)。结论:在激素受体阳性晚期转移性乳腺癌的治疗中联合应用依维莫司和依西美坦,可提高治疗效果,改善生存情况,对炎症因子水平调节作用明显,也可减少药物所致不良反应,可应用。Objective:To analyze the therapeutic effect of everolimus combined with exemestane on hormone receptor-positive advanced metastatic breast cancer.Methods:A total of 72 patients with hormone receptor-positive advanced metastatic breast cancer were selected for the study.They were treated in our hospital from August 2015 to August 2017.They were divided into groups by lottery.There were 36 cases in the control group and the observation group.The control group only used exemestane,and the observation group was used in combination with everolimus and exemestane.The clinical efficacy,survival,and levels of inflammatory factors before and after treatment were compared between the two groups.Results:The total remission rate of the observation group was 58.33%,which was higher than 33.33%of the control group.The median disease progression time was(4.78±1.24)months,and the median overall survival time was(30.12±5.12)months,which was longer than that of the control group.(3.92±1.18)months and(27.32±4.56)months,there was a difference in the comparison between the groups(P<0.05);there was no difference in the levels of inflammatory factors between the two groups before treatment(P>0.05),the observation group had tumor necrosis after treatment The levels of factor-α,interleukin-2,interleukin-6 and interleukin-8 were lower than those of the control group,and there was a difference between the groups(P<0.05).Conclusion:The combined application of everolimus and exemestane in the treatment of hormone-receptor-positive advanced metastatic breast cancer can improve the therapeutic effect,improve survival,and significantly regulate the level of inflammatory factors,and can also reduce drug-induced adverse effects,it can be promoted.

关 键 词：依维莫司 依西美坦 晚期乳腺癌 总缓解率 生存情况 炎症因子 

分 类 号：R737.9[医药卫生—肿瘤]